Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus

Pharmacy World and Science

Volumn 30, Issue 1, 2008, Pages 120-127

  Kamyar, Majidreza ^a   Johnson, B Julienne ^b   McAnaw, John J ^b   Lemmens Gruber, Rosa ^a   Hudson, Steve A ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Cardiovascular disease; Clinical guideline; Community pharmacy; Diabetes mellitus; Primary prevention; Public health; Scotland; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; GLYCEROL NITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; LISINOPRIL; METFORMIN; NITRATE; RAMIPRIL; VERAPAMIL;

ADULT; AGED; ARTICLE; CHI SQUARE TEST; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; FEMALE; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL AUDIT; MEDICAL INFORMATICS; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ASPIRIN; CLINICAL PROTOCOLS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PEER REVIEW; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 36448929758     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9154-7     Document Type: Article

References (21)

1. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005;68:22-9.
2. Niessen LW, Dijkstra R, Hutubessy R, Rutten GE, Casparie AF. Lifetime health effects and costs of diabetes treatment. Neth J Med 2003;61:355-64.
3. Fitzsimons B, Wilton L, Lamont T, McCulloch L, Boyce J. The Audit Commission review of diabetes services in England and Wales, 1998-2001. Diabet Med 2002;19:73-8.
4. Scottish Diabetes Survey Monitoring Group/SEHD. Scottish Diabetes Survey 2001. (Accessed vis http://www.diabetesinscotland.org ).
5. Scottish Executive Health Department. 2002. Scottish Diabetes Framework. Edinburgh: The Stationary Office (April 2003).
6. Diabetes in Minority Ethnic Groups in Scotland. A report by the National Resource Center for Ethnic Minority Health in collaboration with the Scottish Diabetes Group; 2004;Chapters 1 & 2.
7. American Diabetes Association (ADA). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27:5.
8. Rajaei-Dehkordi Z, Hollingshead C, et al. Investigating the contribution of Community pharmacists in identifying, understanding and meeting the needs of patients with diabetes, in collaboration with other healthcare professionals. Int J Pharm Prac 2003;11:R18.
9. Scottish Intercollegiate Guidelines Network. SIGN Publication Number 41. Secondary prevention of coronary heart disease following myocardial infarction. A National Clinical Guideline. Scottish Intercollegiate Guidelines Network: Edinburgh 2000 (accessed via http://www.sign.ac.uk ).
10. Scottish Intercollegiate Guidelines Network. SIGN Publication Number 51. Management of stable angina. A National Clinical Guideline. Scottish Intercollegiate Guidelines Network: Edinburgh 2001 (accessed via http://www.sign.ac.uk ).
11. Chinwong S, Power A, Kesson C, Hudson S. Prescribing for cardioprevention in type 2 diabetes: Adherence to National Guidelines. American Heart Association. 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. Washington. 2004. (published in Circulation 2004;109(20):P200).
12. Scottish Intercollegiate Guidelines Network. SIGN Publication Number 55. Management of Diabetes. A National Clinical Guideline. Scottish Intercollegiate Guidelines Network: Edinburgh 2004 (accessed via http://www.sign.ac.uk ).
13. Ernst A, Kinnear M, Hudson S. Quality of prescribing: A study of guideline adherence of medication in patients with diabetes mellitus. Prac Diab Int 2005;22:285-90.
14. Stratton IM, Adler AI, Neil HA, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 2000;32:405-12.
15. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.
16. Gross R, Tabenkin H, Porath A, et al. The relationship between primary care physicians' adherence to guidelines for the treatment of diabetes and patient satisfaction: findings from a pilot study. Farm Pract 2003;20:563-9.
17. Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res 2005;36:300-6.
18. Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care 2005;11:206-10.
19. Antithrombotic trialists' collaboration. Collaborative meta-analysis of Randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 2002;324:71-86.
20. The Joint British Societies' Guidelines on the Prevention of Cardiovascular Disease in Clinical Practice: Risk Assessment (JBS2 guidelines). January 2006 (Access via http://www.bhsoc.org/bhf_factfiles/ bhf_factfile_jan_2006.pdf ).
21. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82.